Citations (120)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Vaibhav Mehra, Niloy Sarkar, Bibhu Biswal & Mahima Kaushik. (2023) Simulation of nanocarrier-based targeted delivery of an antidepressant for major depressive disorder. Molecular Simulation 49:15, pages 1465-1477.
Read now
Read now
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Felicia Ceban, Saja Jaberi, Leanna M.W. Lui, Emily S. Gillissie, Yazen Alnafeesi, Joshua D. Rosenblat & Roger S. McIntyre. (2022) The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. Expert Opinion on Drug Safety 21:6, pages 841-852.
Read now
Read now
Mitch Earleywine, Brianna R. Altman & Joseph De Leo. (2022) Cognitive Behavioral Therapy, Ketamine, and Combination Treatment for Depression: Impressions of Credibility in Participants with Self-Reported Depressive Symptoms. Journal of Psychoactive Drugs 54:1, pages 70-80.
Read now
Read now
Simon Fifer, Andrea Puig, Vanessa Sequeira, Mustafa Acar, Chee H Ng, Michelle Blanchard, Ariana Cabrera, James Freemantle & Jennifer Grunfeld. (2021) Understanding Treatment Preferences of Australian Patients Living with Treatment-Resistant Depression. Patient Preference and Adherence 15, pages 1621-1637.
Read now
Read now
Joanna Kryst, Paweł Kawalec & Andrzej Pilc. (2020) Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 21:1, pages 9-20.
Read now
Read now
Si-Tien Wang, Ian M Anderson, Dominic Mitchell, Scott J Johnson & Aki Shiozawa. (2019) Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression. ClinicoEconomics and Outcomes Research 11, pages 257-270.
Read now
Read now
Michele Fornaro, Andrea Fusco, Annalisa Anastasia, Carlo Ignazio Cattaneo & Domenico De Berardis. (2019) Brexpiprazole for treatment-resistant major depressive disorder. Expert Opinion on Pharmacotherapy 20:16, pages 1925-1933.
Read now
Read now
Ricardo P. Garay, Thomas Charpeaud, Susan Logan, Patrick Hannaert, Raul G. Garay, Pierre-Michel Llorca & Shefaly Shorey. (2019) Pharmacotherapeutic approaches to treating depression during the perimenopause. Expert Opinion on Pharmacotherapy 20:15, pages 1837-1845.
Read now
Read now
Melvyn W. Zhang & Roger C. Ho. (2017) Ethical Considerations for Clinical Research and Off-label Use of Ketamine to Treat Mood Disorders: The Balance Between Risks and Benefits. Ethics & Behavior 27:8, pages 681-699.
Read now
Read now
Ricardo P. Garay, Carlos A. Zarate$suffix/text()$suffix/text(), Thomas Charpeaud, Leslie Citrome, Christoph U. Correll, Ahcène Hameg & Pierre-Michel Llorca. (2017) Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Review of Neurotherapeutics 17:6, pages 593-609.
Read now
Read now
Tia Sternat & Martin A Katzman. (2016) Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatric Disease and Treatment 12, pages 2149-2164.
Read now
Read now
Articles from other publishers (109)
Nima Sanadgol, Adib Miraki Feriz, Sabrina F. Lisboa & Sâmia R.L. Joca. (2023) Putative role of glial cells in treatment resistance depression: An updated critical literation review and evaluation of single-nuclei transcriptomics data. Life Sciences 331, pages 122025.
Crossref
Crossref
Omar Salem Gammoh & Rasha Bashatwah. (2023) Potential strategies to optimize the efficacy of antidepressants: Beyond the monoamine theory. Electronic Journal of General Medicine 20:5, pages em513.
Crossref
Crossref
Katharina Gryksa, Anna K. Schmidtner, Marianella Masís-Calvo, Odir A. Rodríguez-Villagra, Andrea Havasi, Gwendolyn Wirobski, Rodrigue Maloumby, Herbert Jägle, Oliver J. Bosch, David A. Slattery & Inga D. Neumann. (2023) Selective breeding of rats for high (HAB) and low (LAB) anxiety-related behaviour: A unique model for comorbid depression and social dysfunctions. Neuroscience & Biobehavioral Reviews 152, pages 105292.
Crossref
Crossref
Amie Taggart Blaszczyk, Monica Mathys & Jennifer Le. (2023) A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult. Drugs & Aging 40:9, pages 785-813.
Crossref
Crossref
Rozielly Aparecida Lemes dos Santos, Silvia Regina de Lima Reis, Patrícia Cristiane Gibbert, Cristina Maria de Arruda, Diego Luiz Doneda, Yohan Alves Victor de Matos, Giordano Gubert Viola, Fabrício Rios Santos, Eliângela de Lima, Ziliani da Silva Buss & Samuel Vandresen-Filho. (2023) Guanosine treatment prevents lipopolysaccharide-induced depressive-like behavior in mice. Journal of Psychiatric Research 164, pages 296-303.
Crossref
Crossref
Zhen Tian, Xin-Tong Lu, Xun Jiang & Jiao Tian. (2023) Bryostatin-1: a promising compound for neurological disorders. Frontiers in Pharmacology 14.
Crossref
Crossref
Cherise R. Chin Fatt, Taryn L. Mayes & Madhukar H. Trivedi. (2023) Immune Dysregulation in Treatment-Resistant Depression. Psychiatric Clinics of North America 46:2, pages 403-413.
Crossref
Crossref
Carol Jamieson, Vanina Popova, Ella Daly, Kimberly Cooper, Wayne C. Drevets, Heather M. Rozjabek & Jaskaran Singh. (2023) Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant. Health and Quality of Life Outcomes 21:1.
Crossref
Crossref
Mohd Hanifa, Mohini Singh, Puneet Kaur Randhawa, Amteshwar Singh Jaggi & Anjana Bali. (2023) A focus on Rho/ROCK signaling pathway: An emerging therapeutic target in depression. European Journal of Pharmacology 946, pages 175648.
Crossref
Crossref
Simon Lafrenière, Fatemeh Gholi-Zadeh-Kharrat, Caroline Sirois, Victoria Massamba, Louis Rochette, Camille Brousseau-Paradis, Simon Patry, Christian Gagné, Morgane Lemasson, Geneviève Gariépy, Chantal Mérette, Elham Rahme & Alain Lesage. (2022) The 5-year longitudinal diagnostic profile and health services utilization of patients treated with electroconvulsive therapy in Quebec: a population-based study. Social Psychiatry and Psychiatric Epidemiology 58:4, pages 629-639.
Crossref
Crossref
Lara F. Almutabagani, Raghad A. Almanqour, Jawza F. Alsabhan, Abdulaziz M. Alhossan, Maha A. Alamin, Haya M. Alrajeh, Asma S. Alonazi, Ahmed M. El-Malky & Nouf M. Alrasheed. (2023) Inflammation and Treatment-Resistant Depression from Clinical to Animal Study: A Possible Link?. Neurology International 15:1, pages 100-120.
Crossref
Crossref
日乐 格. (2023) Advances in the Treatment of Treatment-Resistant Depression. Advances in Clinical Medicine 13:03, pages 3860-3865.
Crossref
Crossref
Vasileia Kotoula, Jennifer W. Evans, Claire Punturieri, Sara C. Johnson & Carlos A. ZarateJrJr. 2023. Treatment-Resistant Depression Part A. Treatment-Resistant Depression Part A
117
148
.
Mu-Hong Chen, Pei-Chi Tu & Tung-Ping Su. 2023. Treatment-Resistant Depression Part A. Treatment-Resistant Depression Part A
149
168
.
Sheng-Chiang Wang, Jennifer S. Yokoyama, Nian-Sheng Tzeng, Chia-Fen Tsai & Mu-N Liu. 2023. Treatment-Resistant Depression Part B. Treatment-Resistant Depression Part B
25
53
.
Madeline Brendle, Sachin Ahuja, Maisa Della Valle, Claire Moore, Paul Thielking, Daniel C Malone & Reid Robison. (2022) Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study. Journal of Comparative Effectiveness Research 11:18, pages 1323-1336.
Crossref
Crossref
Madeline Brendle, Reid Robison & Daniel C. Malone. (2022) Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. Journal of Affective Disorders 319, pages 388-396.
Crossref
Crossref
María Yoldi-Negrete, Louis-Nascan Gill, Scarlett Olivares, Anabel Lauzière, Marie Désilets & Smadar Valérie Tourjman. (2022) The effect of continuation and maintenance electroconvulsive therapy on cognition: A systematic review of the literature and meta-analysis. Journal of Affective Disorders 316, pages 148-160.
Crossref
Crossref
Ebru Guclu, Salim Yalcin Inan & Hasibe Cingilli Vural. (2022) The Sirtuin 2 Inhibitor AK-7 Leads to an Antidepressant-Like Effect in Mice via Upregulation of CREB1, BDNF, and NTRK2 Pathways. Molecular Neurobiology 59:11, pages 7036-7044.
Crossref
Crossref
Namrata Hange, Sujan Poudel, Saleha Ozair, Trissa Paul, Meghna Nambakkam, Rakchhya Shrestha, Farrah Greye, Sangam Shah, Yagya Raj Adhikari, Sangharsha Thapa & Pooja Patel. (2022) Managing Chronic Neuropathic Pain: Recent Advances and New Challenges. Neurology Research International 2022, pages 1-14.
Crossref
Crossref
Agnieszka Mechlińska, Adam Włodarczyk, Marta Gruchała-Niedoszytko, Sylwia Małgorzewicz & Wiesław Jerzy Cubała. (2022) Dietary Patterns of Treatment–Resistant Depression Patients. Nutrients 14:18, pages 3766.
Crossref
Crossref
Katarzyna Bialek, Piotr Czarny, Paulina Wigner, Ewelina Synowiec, Lukasz Kolodziej, Michal Bijak, Janusz Szemraj, Mariusz Papp & Tomasz Sliwinski. (2022) Agomelatine Changed the Expression and Methylation Status of Inflammatory Genes in Blood and Brain Structures of Male Wistar Rats after Chronic Mild Stress Procedure. International Journal of Molecular Sciences 23:16, pages 8983.
Crossref
Crossref
Valterlúcio dos Santos Sales, Francisco Romero Cabral, Emmily Petícia do Nascimento Sales, Tatyelle Bezerra Carvalho, Maria Haiele Nogueira Costa, Victor Afonso Pereira de Oliveira, Cristina Kelly de Souza Rodrigues, Francisco Rodolpho Sobreira Dantas Nóbrega de Figueirêdo, Daniel Souza Bezerra, Gyllyandeson de Araújo Delmondes, Henrique Douglas Melo Coutinho, José Galberto Martins da Costa, Irwin Rose Alencar de Menezes, Cícero Francisco Bezerra Felipe & Marta Regina Kerntopf. (2022) Central depressant effects of Piper tuberculatum Jacq essential oil in mice. Food Bioscience 48, pages 101813.
Crossref
Crossref
Jifei Sun, Yue Ma, Limei Chen, Zhi Wang, Chunlei Guo, Yi Luo, Deqiang Gao, Xiaojiao Li, Ke Xu, Yang Hong, Xiaobing Hou, Jing Tian, Xue Yu, Hongxing Wang, Jiliang Fang & Xue Xiao. (2022) Altered Brain Function in Treatment-Resistant and Non-treatment-resistant Depression Patients: A Resting-State Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry 13.
Crossref
Crossref
Urszula Kozlowska, Charles Nichols, Kalina Wiatr & Maciej Figiel. (2021) From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. Journal of Neurochemistry 162:1, pages 89-108.
Crossref
Crossref
Mohammad-Hossein Mohammadi-Mahdiabadi-Hasani, Mohaddeseh Ebrahimi-Ghiri, Fatemeh Khakpai & Mohammad-Reza Zarrindast. (2022) Isobolographic analysis of the antidepressant interaction in two-drug combinations of citalopram, bupropion, and scopolamine in mice. Naunyn-Schmiedeberg's Archives of Pharmacology 395:7, pages 827-837.
Crossref
Crossref
Manoj P. Dandekar, Alexandre P. Diaz, Ziaur Rahman, Ritele H. Silva, Ziad Nahas, Scott Aaronson, Sudhakar Selvaraj, Albert J. Fenoy, Marsal Sanches, Jair C. Soares, Patricio Riva-Posse & Joao Quevedo. (2022) A narrative review on invasive brain stimulation for treatment-resistant depression. Brazilian Journal of Psychiatry 44:3, pages 317-330.
Crossref
Crossref
Marco Antonio Caldieraro, Teng Chei Tung, Lina Maria Agudelo Baena, Manuel Vilapriño Duprat, Ricardo Marcelo Corral, Luis Daniel Alviso de la Serna, Erasmo Saucedo, Gabriela Kanevsky & Patricia Cabrera. (2022) Depression and suicidality severity among TRD patients after 1-year under standard of care: Findings from the TRAL study, a multicenter, multinational, observational study in Latin America. Revista de Psiquiatría y Salud Mental.
Crossref
Crossref
Elizabeth C. Gregory, Ivan J. Torres, Daniel M. Blumberger, Jonathan Downar, Zafiris J. Daskalakis & Fidel Vila-Rodriguez. (2022) Repetitive Transcranial Magnetic Stimulation Shows Longitudinal Improvements in Memory in Patients With Treatment-Resistant Depression. Neuromodulation: Technology at the Neural Interface 25:4, pages 596-605.
Crossref
Crossref
Elizabeth Torres, Katelynn B. Zumpf, Jody D. Ciolino, Crystal T. Clark, Dorothy K. Sit, Emily S. Miller & Katherine L. Wisner. (2022) C-Reactive protein concentrations in reproductive-aged women with major mood disorders. Archives of Women's Mental Health 25:3, pages 577-584.
Crossref
Crossref
Robert Sotille, Herpreet Singh, Anne Weisman & Thomas Vida. (2022) Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus.
Crossref
Crossref
Jieping Lin, Fa Ling, Ping Huang, Min Chen, Min Song, Kangrong Lu & Wanshan Wang. (2022) The Development of GABAergic Network in Depression in Recent 17 Years: A Visual Analysis Based on CiteSpace and VOSviewer. Frontiers in Psychiatry 13.
Crossref
Crossref
Nicolas Upton. (2021) Developing our understanding of nutrition in depression. British Journal of Nutrition 127:7, pages 1010-1017.
Crossref
Crossref
Amaya Austrich-Olivares, María Salud García-Gutiérrez, Lucía Illescas, Ani Gasparyan & Jorge Manzanares. (2022) Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice. Pharmaceuticals 15:4, pages 473.
Crossref
Crossref
Éva Borbély, Mária Simon, Eberhard Fuchs, Ove Wiborg, Boldizsár Czéh & Zsuzsanna Helyes. (2022) Novel drug developmental strategies for treatment‐resistant depression. British Journal of Pharmacology 179:6, pages 1146-1186.
Crossref
Crossref
Tácio de Mendonça Lima, Marília Berlofa Visacri & Patricia Melo Aguiar. (2021) Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. European Journal of Clinical Pharmacology 78:3, pages 311-338.
Crossref
Crossref
Ya-Ting Wang, Ning-Ning Zhang, Ling-Jie Liu, Hong Jiang, Die Hu, Zhen-Zhen Wang, Nai-Hong Chen & Yi Zhang. (2022) Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants. Biochemical and Biophysical Research Communications 594, pages 46-56.
Crossref
Crossref
Antonio Tundo, Sophia Betro'Marica Iommi & Rocco de Filippis. (2022) Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 112, pages 110425.
Crossref
Crossref
Shangyan Gao, Xueling Zhang, Hui Xu, Dongjin Miao, Jiaoni Qian, Zhonghua Wu & Weihua Shi. (2022) Promoting the hippocampal PPARα expression participates in the antidepressant mechanism of reboxetine, a selective norepinephrine reuptake inhibitor. Behavioural Brain Research 416, pages 113535.
Crossref
Crossref
Manpreet Kaur, Rupinder Kaur Sodhi, Vaskuri G.S. Sainaga Jyothi, Veerabomma Haritha Sree, Shubhra, Pankaj Kumar Singh, Neelesh Kumar Mehra, Dharmendra Kumar Khatri, Saurabh Srivastava, Shashi Bala Singh, Jitender Madan & Satish Sardana. 2022. Multifunctional Nanocarriers. Multifunctional Nanocarriers
289
345
.
David S. KrollDavid S. Kroll. 2022. Caring for Patients with Depression in Primary Care. Caring for Patients with Depression in Primary Care
61
73
.
Anderson Camargo, Ana Paula Dalmagro, Ingrid A.V. Wolin, Manuella P. Kaster & Ana Lúcia S. Rodrigues. (2021) The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway. Journal of Psychiatric Research 144, pages 118-128.
Crossref
Crossref
Zoe Schreiber, Chenyang Wang, Amanda Tan, Patricio Riva-Posse, William M. McDonald, Andrea Crowell, Adriana P. Hermida & Rachel Hershenberg. (2021) Do baseline anxiety symptoms impact response to IV Ketamine in treatment resistant depression?. Journal of Affective Disorders Reports 6, pages 100253.
Crossref
Crossref
Bernardo Soares, Gabriela Kanevsky, Chei Tung Teng, Rodrigo Pérez-Esparza, Gerardo Garcia Bonetto, Acioly L. T. Lacerda, Erasmo Saucedo Uribe, Rodrigo Cordoba, Christian Lupo, Aline Medeiros Samora & Patricia Cabrera. (2021) Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study. Psychiatric Quarterly 92:4, pages 1797-1815.
Crossref
Crossref
Vikas MenonNivedhitha SelvakumarAbdul Faheem. (2021) Selection of psychotropics in dermatologic practice. Cosmoderma 1, pages 60.
Crossref
Crossref
Giulio Perugi, Paola Calò, Sergio De Filippis, Gianluca Rosso, Antonio Vita, Marina Adami, Giuseppe Ascione, Joachim Morrens & Dario Delmonte. (2021) Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective Study. Frontiers in Psychiatry 12.
Crossref
Crossref
Victor Augusto Rodovalho Fava, Luciana Maria Sarin, Ana Cecília Lucchese, Lorena Del Sant, Eduardo Magalhães, Rodrigo Simonini Delfino, Marco Aurélio Tuena, Carolina Nakahira, Andrea Parolin Jackowski, Guilherme Abdo, Juliana Surjan, Matheus Steiglich, Matheus Ghossain Barbosa, José Alberto Del Porto, Acioly Luiz Tavares Lacerda & Hugo Cogo-Moreira. (2021) The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression. Revista de Psiquiatría y Salud Mental (English Edition) 14:4, pages 212-217.
Crossref
Crossref
Victor Augusto Rodovalho Fava, Luciana Maria Sarin, Ana Cecília Lucchese, Lorena Del Sant, Eduardo Magalhães, Rodrigo Simonini Delfino, Marco Aurélio Tuena, Carolina Nakahira, Andrea Parolin Jackowski, Guilherme Abdo, Juliana Surjan, Matheus Steiglich, Matheus Ghossain Barbosa, José Alberto Del Porto, Acioly Luiz Tavares Lacerda & Hugo Cogo-Moreira. (2021) The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression. Revista de Psiquiatría y Salud Mental 14:4, pages 212-217.
Crossref
Crossref
Marlies E Alvarenga, Barbara M Murphy & Alun C Jackson. (2021) Emerging approaches to the treatment of depression in patients with cardiovascular disease. British Journal of Cardiac Nursing 16:9, pages 1-4.
Crossref
Crossref
Chiara Fabbri, Oliver Pain, Saskia P. Hagenaars, Cathryn M. Lewis & Alessandro Serretti. (2021) Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. Neuropsychopharmacology 46:10, pages 1821-1829.
Crossref
Crossref
Maryia Zhdanava, Swapna Karkare, Dominic Pilon, Kruti Joshi, Carmine Rossi, Laura Morrison, John Sheehan, Patrick Lefebvre, Oliver Lopena & Leslie Citrome. (2021) Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression. Advances in Therapy 38:9, pages 4900-4916.
Crossref
Crossref
Alisha Sapkota, Hajra Khurshid, Israa A Qureshi, Nasrin Jahan, Terry R Went, Waleed Sultan & Michael Alfonso. (2021) Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review. Cureus.
Crossref
Crossref
K. Heerlein, G. Perugi, C. Otte, T. Frodl, G. Degraeve, W. Hagedoorn, A.J. Oliveira-Maia, V. Perez Sola, S. Rathod, G. Rosso, P. Sierra, S. Malynn, J. Morrens, C. Verrijcken, B. Gonzalez & A.H. Young. (2021) Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes. Journal of Affective Disorders 290, pages 334-344.
Crossref
Crossref
Phatcharee Chukaew, Alex Leow, Witchuda Saengsawang & Mark M. Rasenick. (2020) Potential depression and antidepressant-response biomarkers in human lymphoblast cell lines from treatment-responsive and treatment-resistant subjects: roles of SSRIs and omega-3 polyunsaturated fatty acids. Molecular Psychiatry 26:6, pages 2402-2414.
Crossref
Crossref
Sandesh P. Kamdi, Amit Raval & Kartik T. Nakhate. (2021) Phloridzin ameliorates type 2 diabetes‐induced depression in mice by mitigating oxidative stress and modulating brain‐derived neurotrophic factor. Journal of Diabetes & Metabolic Disorders 20:1, pages 341-348.
Crossref
Crossref
Natalia Górska, Wiesław Jerzy Cubała, Jakub Słupski, Mariusz Stanisław Wiglusz, Maria Gałuszko-Węgielnik, Mateusz Kawka & Agata Grzegorzewska. (2021) Magnesium in Ketamine Administration in Treatment-Resistant Depression. Pharmaceuticals 14:5, pages 430.
Crossref
Crossref
Jun Shen, Lu Yang & Wenshi Wei. (2021) Role of Fto on CaMKII/CREB signaling pathway of hippocampus in depressive-like behaviors induced by chronic restraint stress mice. Behavioural Brain Research 406, pages 113227.
Crossref
Crossref
Katarzyna Bialek, Piotr Czarny, Paulina Wigner, Ewelina Synowiec, Gabriela Barszczewska, Michal Bijak, Janusz Szemraj, Monika Niemczyk, Katarzyna Tota-Glowczyk, Mariusz Papp & Tomasz Sliwinski. (2021) Chronic Mild Stress and Venlafaxine Treatment Were Associated with Altered Expression Level and Methylation Status of New Candidate Inflammatory Genes in PBMCs and Brain Structures of Wistar Rats. Genes 12:5, pages 667.
Crossref
Crossref
Chenguang Jiang, Hongliang Zhou, Limin Chen & Zhenhe Zhou. (2021) Problem Solving Therapy Improves Effortful Cognition in Major Depression. Frontiers in Psychiatry 12.
Crossref
Crossref
Mayank. S. Jog, Elizabeth Kim, Cole Anderson, Antoni Kubicki, Rishikesh Kayathi, Kay Jann, Lirong Yan, Amber Leaver, Gerhard Hellemann, Marco Iacoboni, Roger P. Woods, Danny J. J. Wang & Katherine L. Narr. (2021) In-vivo imaging of targeting and modulation of depression-relevant circuitry by transcranial direct current stimulation: a randomized clinical trial. Translational Psychiatry 11:1.
Crossref
Crossref
Angelos Halaris, Emilie Sohl & Elizabeth A. Whitham. (2021) Treatment-Resistant Depression Revisited: A Glimmer of Hope. Journal of Personalized Medicine 11:2, pages 155.
Crossref
Crossref
Weifen Li, Tahir Ali, Chengyou Zheng, Zizhen Liu, Kaiwu He, Fawad Ali Shah, Qingguo Ren, Shafiq Ur Rahman, Ningning Li, Zhi-Jian Yu & Shupeng Li. (2021) Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression. Journal of Neuroinflammation 18:1.
Crossref
Crossref
Sara Dodić, Bojana Dunjić-Kostić, Stefan Jerotić, Nikola Lalović, Maja Ivković & Maja Pantović-Stefanović. (2021) Cariprazine in the treatment of unipolar depression: Case report. Engrami 43:1, pages 82-98.
Crossref
Crossref
Chi-Wei Lee, Han-Fang Wu, Ming-Chia Chu, Yueh-Jung Chung, Wei-Chang Mao, Cheng-Ta Li & Hui-Ching Lin. (2021) Mechanism of Intermittent Theta-Burst Stimulation in Synaptic Pathology in the Prefrontal Cortex in an Antidepressant-Resistant Depression Rat Model. Cerebral Cortex 31:1, pages 575-590.
Crossref
Crossref
Megumi Kinjo, Masataka Wada, Shinichiro Nakajima, Sakiko Tsugawa, Tomomi Nakahara, Daniel M. Blumberger, Masaru Mimura & Yoshihiro Noda. (2020) Transcranial magnetic stimulation neurophysiology of patients with major depressive disorder: a systematic review and meta-analysis. Psychological Medicine 51:1, pages 1-10.
Crossref
Crossref
Chiara Fabbri, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Marco Andrea Riva, Cathryn M. Lewis & Alessandro Serretti. (2021) Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 104, pages 110050.
Crossref
Crossref
Sophie R. Vaccarino & Sidney H. Kennedy. 2021. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
33
84
.
Matea Nikolac Perkovic, Marina Sagud, Lucija Tudor, Marcela Konjevod, Dubravka Svob Strac & Nela Pivac. 2021. Major Depressive Disorder. Major Depressive Disorder
175
202
.
Emilio Garro-Martínez & Albert Adell. 2021. New Rapid-acting Antidepressants. New Rapid-acting Antidepressants
85
109
.
Fay A. Guarraci, Maryam Ali, Chantal M.F. Gonzalez, Devon Lucero, Larry W. Clemons, Lourdes K. Davis, Elizabeth L. Henneman, Shannon E. Odell & Sarah H. Meerts. (2020) I. Antidepressants and sexual behavior: Weekly ketamine injections increase sexual behavior initially in female and male rats. Pharmacology Biochemistry and Behavior 199, pages 173039.
Crossref
Crossref
Po-Sheng Yang, Hsien-Yu Peng, Tzer-Bin Lin, Ming-Chun Hsieh, Cheng-Yuan Lai, An-Sheng Lee, Hsueh-Hsiao Wang & Yu-Cheng Ho. (2020) NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray. Neuropharmacology 178, pages 108269.
Crossref
Crossref
Chong-Su Kim, Seohyeon Byeon & Dong-Mi Shin. (2020) Sources of Dietary Fiber Are Differently Associated with Prevalence of Depression. Nutrients 12:9, pages 2813.
Crossref
Crossref
Elizabeth Gregory, Ivan J. Torres, Ruiyang Ge, Daniel M. Blumberger, Jonathan H. Downar, Zafiris J. Daskalakis, Raymond W. Lam & Fidel Vila-Rodriguez. (2020) Predictors of cognitive impairment in treatment-resistant depression. Journal of Affective Disorders 274, pages 593-601.
Crossref
Crossref
Kristine Tveit, Monica Hermann, Ragnhild Birkeland Waade, Roy Miodini Nilsen, Susanna M. Wallerstedt & Espen Molden. (2020) Use of Antidepressants in Older People during a 10-Year Period: An Observational Study on Prescribed Doses and Serum Levels. Drugs & Aging 37:9, pages 691-701.
Crossref
Crossref
Thiago B. Kirsten, Danilo Cabral, Marcella C. Galvão, Renan Monteiro, Eduardo F. Bondan & Maria Martha Bernardi. (2020) Zinc, but not paracetamol, prevents depressive-like behavior and sickness behavior, and inhibits interferon-gamma and astrogliosis in rats. Brain, Behavior, and Immunity 87, pages 489-497.
Crossref
Crossref
Irving S. Aguilar-Martinez, Miriam E. Reyes-Mendez, J. Manuel Herrera-Zamora, Fernando Osuna-Lopez, Adolfo Virgen-Ortiz, Nestor Mendoza-Munoz, Jose L. Gongora-Alfaro, Eloy G. Moreno-Galindo & Javier Alamilla. (2020) Synergistic antidepressant-like effect of capsaicin and citalopram reduces the side effects of citalopram on anxiety and working memory in rats. Psychopharmacology 237:7, pages 2173-2185.
Crossref
Crossref
Albert Adell. (2020) Brain NMDA Receptors in Schizophrenia and Depression. Biomolecules 10:6, pages 947.
Crossref
Crossref
Paulina Wigner, Ewelina Synowiec, Piotr Czarny, Michal Bijak, Paweł Jóźwiak, Janusz Szemraj, Piotr Gruca, Mariusz Papp & Tomasz Śliwiński. (2020) Effects of venlafaxine on the expression level and methylation status of genes involved in oxidative stress in rats exposed to a chronic mild stress. Journal of Cellular and Molecular Medicine 24:10, pages 5675-5694.
Crossref
Crossref
R. Gregory Lande. (2020) Nutraceutical Augmentation Strategies for Depression: A Narrative Review. Journal of Osteopathic Medicine 120:2, pages 100-106.
Crossref
Crossref
Foluso AgboolaSteven J. Atlas, Daniel R. TouchetteKatherine FazioliSteven D. Pearson. (2020) The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy 26:1, pages 16-20.
Crossref
Crossref
Siyan Fan, Samaneh Nemati, Teddy J. Akiki, Jeremy Roscoe, Christopher L. Averill, Samar Fouda, Lynnette A. Averill & Chadi G. Abdallah. (2020) Pretreatment Brain Connectome Fingerprint Predicts Treatment Response in Major Depressive Disorder. Chronic Stress 4, pages 247054702098472.
Crossref
Crossref
Meritxell Tost, José Antonio Monreal, Antonio Armario, Juan David Barbero, Jesús Cobo, Clemente García-Rizo, Miquel Bioque, Judith Usall, Elena Huerta-Ramos, Virginia Soria & Javier Labad. (2019) Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin. Clinical Drug Investigation 40:1, pages 1-14.
Crossref
Crossref
Giulia Lombardo, Daniela Enache, Laura Gianotti, Alan F. Schatzberg, Allan H. Young, Carmine M. Pariante & Valeria Mondelli. (2019) Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis. Psychoneuroendocrinology 110, pages 104420.
Crossref
Crossref
Andreia Gapski, Trilicia M. Gomes, Maiara A. Bredun, Nayla E. Ferreira-Lima, Fabiana Kalyne Ludka, Marilde T. Bordignon-Luiz & Vívian Maria Burin. (2019) Digestion behavior and antidepressant-like effect promoted by acute administration of blueberry extract on mice. Food Research International 125, pages 108618.
Crossref
Crossref
Marco Del Giudice. (2019) Invisible Designers: Brain Evolution Through the Lens of Parasite Manipulation. The Quarterly Review of Biology 94:3, pages 249-282.
Crossref
Crossref
Xavier López-Gil, Laura Jiménez-Sánchez, Leticia Campa, Elena Castro, Clara Frago & Albert Adell. (2019) Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine. ACS Chemical Neuroscience 10:7, pages 3318-3326.
Crossref
Crossref
Javier Labad, Virginia Soria, Antonio Armario, Roser Nadal, José Antonio Monreal & Diego Palao. (2019) Levothyroxine treatment for persistent cognitive symptoms in major depression. Revista de Psiquiatría y Salud Mental (English Edition) 12:3, pages 199-200.
Crossref
Crossref
Javier Labad, Virginia Soria, Antonio Armario, Roser Nadal, José Antonio Monreal & Diego Palao. (2019) Tratamiento con levotiroxina de los síntomas cognitivos persistentes en depresión mayor. Revista de Psiquiatría y Salud Mental 12:3, pages 199-200.
Crossref
Crossref
Chi-Wei Lee, Yi-Ju Chen, Han-Fang Wu, Yueh-Jung Chung, Yi-Chao Lee, Cheng-Ta Li & Hui-Ching Lin. (2019) Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 93, pages 102-113.
Crossref
Crossref
Boadie W. DunlopDevon LoParoBecky KinkeadTanja Mletzko-CroweSteven P. ColeCharles B. NemeroffHelen S. MaybergW. Edward Craighead. (2019) Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. American Journal of Psychiatry 176:4, pages 275-286.
Crossref
Crossref
Peter Dome, Laszlo Tombor, Judit Lazary, Xenia Gonda & Zoltan Rihmer. (2019) Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. Brain Research Bulletin 146, pages 51-78.
Crossref
Crossref
Cristina Cusin & Stefan Peyda. 2019. The Massachusetts General Hospital Guide to Depression. The Massachusetts General Hospital Guide to Depression
3
19
.
Chunxiao Wu, Peihui Liu, Huaili Fu, Wentao Chen, Shaoyang CuiLiming Lu & Chunzhi Tang. (2018) Transcutaneous auricular vagus nerve stimulation in treating major depressive disorder. Medicine 97:52, pages e13845.
Crossref
Crossref
E. Wajs, L. Aluisio, R. Morrison, E. Daly, R. Lane, P. Lim, R. Holder, G. Sanacora, A. Young, S. Kasper, A. Sulaiman, C. Li, J.W. Paik, H. Manji, D. Hough, W. Drevets & J. Singh. (2018) Etude de phase 3 en ouvert évaluant l’efficacité et la sécurité d’emploi à long terme d’Eskétamine intranasal (ESK IN) associé à un antidépresseur oral chez des patients atteints de dépression résistante (SUSTAIN-2). French Journal of Psychiatry 1, pages S176.
Crossref
Crossref
Jerome Sarris, Gerard J. Byrne, Chad Bousman, Con Stough, Jenifer Murphy, Patricia MacDonald, Laura Adams, Sonia Nazareth, Georgina Oliver, Lachlan Cribb, Karen Savage, Ranjit Menon, Suneel Chamoli, Michael Berk, Chee Ng & David Mischoulon. (2018) Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial,. European Neuropsychopharmacology 28:10, pages 1126-1136.
Crossref
Crossref
Zhenghua Hou, Youyong Kong, Xiaofu He, Yingying Yin, Yuqun Zhang & Yonggui Yuan. (2018) Increased temporal variability of striatum region facilitating the early antidepressant response in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 85, pages 39-45.
Crossref
Crossref
Jörg Mahlich, Sunny Tsukazawa & Frank Wiegand. (2017) Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs - Real World Outcomes 5:1, pages 35-43.
Crossref
Crossref
Takeshi Inoue, Akira Nishimura, Kiyofumi Sasai & Tadayuki Kitagawa. (2017) Randomized, 8‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial. Psychiatry and Clinical Neurosciences 72:2, pages 103-115.
Crossref
Crossref
Chadi G. Abdallah, Christopher L. Averill, Ramiro Salas, Lynnette A. Averill, Philip R. Baldwin, John H. Krystal, Sanjay J. Mathew & Daniel H. Mathalon. (2017) Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2:7, pages 566-574.
Crossref
Crossref
Karen A. Scott, Annette D. de Kloet, Michael D. Smeltzer, Eric G. Krause, Jonathan N. Flak, Susan J. Melhorn, Michelle T. Foster, Kellie L.K. Tamashiro & Randall R. Sakai. (2017) Susceptibility or resilience? Prenatal stress predisposes male rats to social subordination, but facilitates adaptation to subordinate status. Physiology & Behavior 178, pages 117-125.
Crossref
Crossref
Zhuo Chen, Chao Huang, Haiyan He & Wenbin Ding. (2017) 2, 3, 5, 4′-Tetrahydroxystilbene-2-O-β-d-glucoside prevention of lipopolysaccharide-induced depressive-like behaviors in mice involves neuroinflammation and oxido-nitrosative stress inhibition. Behavioural Pharmacology 28:5, pages 365-374.
Crossref
Crossref
Daniel L. Alkon, Jarin Hongpaisan & Miao-Kun Sun. (2017) Effects of chronic bryostatin-1 on treatment-resistant depression in rats. European Journal of Pharmacology 807, pages 71-74.
Crossref
Crossref
Julia Kleeblatt, Felix Betzler, Laura L. Kilarski, Tom Bschor & Stephan Köhler. (2017) Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence. European Neuropsychopharmacology 27:5, pages 423-441.
Crossref
Crossref
D F Ionescu & G I Papakostas. (2017) Experimental medication treatment approaches for depression. Translational Psychiatry 7:3, pages e1068-e1068.
Crossref
Crossref
Zongling He, Qian Cui, Junjie Zheng, Xujun Duan, Yajing Pang, Qing Gao, Shaoqiang Han, Zhiliang Long, Yifeng Wang, Jiao Li, Xiao Wang, Jingping Zhao & Huafu Chen. (2016) Frequency-specific alterations in functional connectivity in treatment-resistant and -sensitive major depressive disorder. Journal of Psychiatric Research 82, pages 30-39.
Crossref
Crossref
Douglas G. Kondo, Lauren N. Forrest, Xianfeng Shi, Young-Hoon Sung, Tracy L. Hellem, Rebekah S. Huber & Perry F. Renshaw. (2016) Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids 48:8, pages 1941-1954.
Crossref
Crossref
Ali M. Hashmi, Imran S. Khawaja & Asim A. Shah. (2016) A 35-Year-Old Man with Depressed Mood, Insomnia, and Suicidal Ideation. Psychiatric Annals 46:4, pages 216-218.
Crossref
Crossref
Rui Lopes, José Carlos Alves & Raquel Garcia Rego. (2016) Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants. Case Reports in Medicine 2016, pages 1-6.
Crossref
Crossref
Francisco López-Muñoz, Cecilio Álamo & Pilar García-García. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
421
444
.